Mineralys Therapeutics, Inc. (MLYS)
(Real Time Quote from BATS)
$13.92 USD
+0.22 (1.61%)
Updated Oct 16, 2024 03:58 PM ET
3-Hold of 5 3
D Value F Growth C Momentum F VGM
Mineralys Therapeutics, Inc. (MLYS) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$33.14 | $45.00 | $26.00 | 141.90% |
Price Target
Based on short-term price targets offered by seven analysts, the average price target for Mineralys Therapeutics, Inc. comes to $33.14. The forecasts range from a low of $26.00 to a high of $45.00. The average price target represents an increase of 141.9% from the last closing price of $13.70.
Analyst Price Targets (7 )
Broker Rating
Mineralys Therapeutics, Inc. currently has an average brokerage recommendation (ABR) of 1.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by seven brokerage firms. The current ABR compares to an ABR of 1.00 a month ago based on seven recommendations.
Of the seven recommendations deriving the current ABR, seven are Strong Buy, representing 100% of all recommendations. A month ago, Strong Buy represented 100%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 7 | 7 | 7 | 7 | 7 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
10/2/2024 | Guggenheim Securities | Seamus Fernandez | Strong Buy | Strong Buy |
8/13/2024 | Wells Fargo Securities | Mohit Bansal | Strong Buy | Strong Buy |
8/13/2024 | LifeSci Capital | Rami Katkhuda | Strong Buy | Strong Buy |
8/13/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
7/10/2024 | H.C. Wainwright & Co. | Matthew Caufield | Not Available | Strong Buy |
4/2/2024 | Goldman Sachs | Richard Law | Not Available | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.00 |
ABR (Last week) | 1.00 |
# of Recs in ABR | 7 |
Average Target Price | $33.14 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 91 of 252 |
Current Quarter EPS Est: | -0.83 |
MLYS FAQs
Mineralys Therapeutics, Inc. (MLYS) currently has an average brokerage recommendation (ABR) of 1.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 7 brokerage firms.
The average price target for Mineralys Therapeutics, Inc. (MLYS) is $33.14. The current on short-term price targets is based on 4 reports.
The forecasts for Mineralys Therapeutics, Inc. (MLYS) range from a low of $26 to a high of $45. The average price target represents a increase of $141.90 from the last closing price of $13.70.
The current UPSIDE for Mineralys Therapeutics, Inc. (MLYS) is 141.90%
Based on short-term price targets offered by seven analysts, the average price target for Mineralys Therapeutics, Inc. comes to $33.14. The forecasts range from a low of $26.00 to a high of $45.00. The average price target represents an increase of 141.9% from the last closing price of $13.70.